We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
Cap. Flow
-$233M
Cap. Flow %
-3.6%
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$249M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$112M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$71.9M
4
ENDP
Endo International plc
ENDP
+$58M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$53M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
BIIB icon
Biogen
BIIB
+$235M
3
AGN
Allergan plc
AGN
+$128M
4
CVS icon
CVS Health
CVS
+$52M
5
CNC icon
Centene
CNC
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 1.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
126
DELISTED
Allakos
ALLK
– –
-175,000
Closed -$9.15M
BLUE
127
DELISTED
bluebird bio
BLUE
– –
-29,892
Closed -$38.4M
BSX icon
128
CALL
Boston Scientific
BSX
$69.1B
– –
-250,000
Closed -$8.84M
CNC icon
129
Centene
CNC
$31.2B
– –
-834,800
Closed -$48.1M
CVS icon
130
CVS Health
CVS
$138B
– –
-793,800
Closed -$52M
DVA icon
131
DaVita
DVA
$15.5B
– –
-534,000
Closed -$27.5M
ECOR icon
132
electroCore
ECOR
$51.4M
– –
-26,548
Closed -$2.49M
HCA icon
133
HCA Healthcare
HCA
$90.8B
– –
-75,900
Closed -$9.45M
IRWD icon
134
Ironwood Pharmaceuticals
IRWD
$604M
– –
-3,436,332
Closed -$29.8M
MOH icon
135
Molina Healthcare
MOH
$10.5B
– –
-305,000
Closed -$35.4M
PFE icon
136
Pfizer
PFE
$144B
– –
-634,719
Closed -$26.3M
RDHL
137
Redhill Biopharma
RDHL
$4.26M
– –
-55
Closed -$303K
SAGE
138
DELISTED
Sage Therapeutics
SAGE
– –
-36,300
Closed -$3.48M
THC icon
139
Tenet Healthcare
THC
$22.3B
– –
-562,785
Closed -$9.65M
UNH icon
140
UnitedHealth
UNH
$387B
– –
-186,500
Closed -$46.5M
VTAK icon
141
Catheter Precision
VTAK
$1.03M
– –
-1
Closed -$2.78M
YI
142
111 Inc
YI
$33.4M
– –
-50,000
Closed -$3.07M
ALIM
143
DELISTED
Alimera Sciences
ALIM
– –
-16,667
Closed -$180K
ICPT
144
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-66,000
Closed -$6.65M
ICPT
145
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-47,800
Closed -$4.82M
SPPI
146
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-2,265,500
Closed -$19.8M
ADMS
147
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-100,000
Closed -$854K
IMMU
148
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-100,000
Closed -$1.43M
AGN
149
DELISTED
Allergan plc
AGN
– –
-957,000
Closed -$128M
DERM
150
DELISTED
Dermira, Inc.
DERM
– –
-1,031,596
Closed -$7.42M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2019 Portfolio in Review

As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Alector worth $247M.

  • OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
  • OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
  • OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
  • OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
  • OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
  • OrbiMed opened 25 new positions and closed 31 in Q1 2019.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.